Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy
Clinical trial NCT04694781 · COMPLETED
Trial details
- NCT number
- NCT04694781
- Sponsor
- Lyvgen Biopharma Holdings Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-14
- Primary completion
- 2023-10-31
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.